Hinova Pharmaceuticals (SHSE:688302) ROCE % : -16.04% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hinova Pharmaceuticals's annualized ROCE % for the quarter that ended in Jun. 2024 was -16.04%.

Hinova Pharmaceuticals ROCE % Historical Data

The historical data trend for Hinova Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals ROCE % Chart

Hinova Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-102.71

-34.12

-24.93

-19.63

Hinova Pharmaceuticals Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial													-23.63	-19.98	-15.92	-13.80	-16.04

Hinova Pharmaceuticals ROCE % Calculation

Hinova Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-292.652	/	( ( (1735.074 - 138.271)	+	(1491.565 - 106.845) )	/ 2 )
	=	-292.652	/	( (1596.803	+	1384.72)	/ 2 )
	=	-292.652	/	1490.7615
	=	-19.63 %

Hinova Pharmaceuticals's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-212.268	/	( ( (1434.439 - 90.576)	+	(1445.184 - 141.861) )	/ 2 )
	=	-212.268	/	( ( 1343.863	+	1303.323 )	/ 2 )
	=	-212.268	/	1323.593
	=	-16.04 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Hinova Pharmaceuticals (SHSE:688302) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hinova Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041

Website

http://www.hinovapharma.com

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines